Boost, a popular health drink, and Crocin, a widely used analgesic medicine, are brands owned by which multinational healthcare and consumer products company?

Introduction / Context:
This question connects business awareness with everyday consumer products. Boost is a nutritional health drink heavily advertised in India, often with sports themes, while Crocin is a well known brand of paracetamol based pain relief tablets and syrups. The question asks which multinational company owns these two brands. Understanding which corporation controls widely used products helps candidates see how pharmaceutical and health drink markets are consolidated under a few global players, and it improves recall for brand related general knowledge questions.

Given Data / Assumptions:
- Two brand names are given: Boost (a health drink) and Crocin (a medicine for fever and pain relief).
- The options are GlaxoSmithKline, Pfizer, Heinz and Paras Pharma.
- We assume the question refers to the period when both brands were managed within the same corporate group as per standard exam references.
- The focus is on brand ownership rather than on which company manufactures them under contract.

Concept / Approach:
GlaxoSmithKline (GSK) Consumer Healthcare had a strong portfolio in India that included Boost as a major malt based health drink alongside Horlicks, as well as Crocin as a popular over the counter analgesic and antipyretic medicine. Boost has been promoted with sports celebrities and stamina related slogans, while Crocin is familiar to households for fever and headache relief. Pfizer is another big pharmaceutical company, Heinz is known for foods like ketchup and Complan, and Paras Pharma deals with various personal care and over the counter brands. However, the specific combination of Boost and Crocin under one corporate owner corresponds to GlaxoSmithKline.

Step-by-Step Solution:
Step 1: Recognise that Boost is a malt based health drink, while Crocin is a paracetamol based medicine. Step 2: Recall that GSK Consumer Healthcare in India has managed both nutrition drinks and pain relief medicines, including Boost and Crocin. Step 3: Check the other options: Pfizer is more focused on prescription drugs, Heinz on foods and nutritional drinks like Complan, and Paras Pharma on personal care and some over the counter products. Step 4: Conclude that GlaxoSmithKline is the correct answer because it is the commonly cited owner of both brands in exam oriented material.

Verification / Alternative check:
A verification technique is to remember television advertisements and packaging. Boost packs often carried the GSK Consumer Healthcare identity, and Crocin strips and cartons also displayed the GSK name or logo, especially in earlier packaging. Heinz advertising in India focuses more on Complan and ketchup, not on Crocin or Boost. Pfizer's name is usually seen in prescription medicines and vaccines rather than a mass market health drink like Boost. Paras Pharma is remembered for brands like Moov or Livon, not for Crocin. This pattern confirms that GSK is the right choice.

Why Other Options Are Wrong:
Pfizer: An important pharmaceutical company, but it is not the widely recognised brand owner of Boost and Crocin in standard general knowledge references.
Heinz: Known for its food products and drinks like Complan, but does not manage Crocin as a pain relief brand.
Paras Pharma: Associated with other consumer healthcare brands, but not the owner of both Boost and Crocin.

Common Pitfalls:
Students may incorrectly pick Heinz because of its association with nutritional drinks or may guess Pfizer simply due to its strong pharmaceutical reputation. Another common error is to overlook the fact that a single company needs to own both brands, not just one of them. To avoid confusion, pay attention to product packaging and corporate names when buying or seeing common medicines and drinks; combining this everyday observation with revision material will make such questions easier to answer.

Final Answer:
Boost and Crocin are brands owned by GlaxoSmithKline, making GlaxoSmithKline the correct answer.